OverviewSuggest Edit

Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam.

TypePublic
Founded2006
HQMalvern, US
Websiterecropharma.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Sep 2017)195
Job Openings8
Revenue (FY, 2018)$77.3 M(+8%)
Share Price (Mar 2019)$9.2 (+3%)

Key People/Management at Recro Pharma

Gerri Henwood

Gerri Henwood

President & Chief Executive Officer
Michael Celano

Michael Celano

COO
Ryan D. Lake

Ryan D. Lake

CFO
Stewart McCallum

Stewart McCallum

Chief Medical Officer
Fred Graff

Fred Graff

Chief Commercial Officer
Randy Mack

Randy Mack

Senior Vice President, Development
Show more

Recro Pharma Office Locations

Recro Pharma has an office in Malvern
Malvern, US (HQ)
490 Lapp Rd
Show all (1)
Report incorrect company information

Recro Pharma Financials and Metrics

Recro Pharma Revenue

Recro Pharma's revenue was reported to be $77.35 m in FY, 2018
USD

Revenue (FY, 2018)

77.3m

Gross profit (FY, 2018)

34.2m

Gross profit margin (FY, 2018), %

44.2%

Net income (FY, 2018)

(79.7m)

EBIT (FY, 2018)

(54.0m)

Market capitalization (15-Mar-2019)

202.1m

Closing stock price (15-Mar-2019)

9.2

Cash (31-Dec-2018)

38.5m

EV

227.8m
Recro Pharma's current market capitalization is $202.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

52.0m69.3m71.8m77.3m

Revenue growth, %

33%

Cost of goods sold

28.1m37.2m38.2m43.2m

Gross profit

23.9m32.2m33.6m34.2m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

18.7m16.5m17.7m17.3m17.0m18.7m16.9m17.1m19.5m21.7m18.3m

Cost of goods sold

9.4m10.0m10.3m9.5m5.7m10.5m10.4m6.9m10.5m12.1m8.5m

Gross profit

9.3m6.5m7.5m7.7m11.2m8.2m6.5m10.2m9.1m9.7m9.8m

Gross profit Margin, %

50%39%42%45%66%44%38%60%46%44%54%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

19.7m19.8m64.5m61.0m38.5m

Accounts Receivable

89.6k8.6m10.4m9.7m12.9m

Inventories

9.0m1.1m9.8m10.7m

Current Assets

20.4m38.7m84.8m87.3m71.1m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

29.9m27.8m23.9m16.6m15.7m28.3m14.9m14.8m24.8m19.5m8.7m11.8m46.3m48.9m35.8m

Accounts Receivable

35.8k86.8k80.2k15.0m9.6m12.2m11.5m12.4m12.3m10.1m13.1m9.8m11.7m11.7m

Inventories

9.6m8.6m7.6m6.7m9.8m7.8m6.9m9.9m10.0m8.1m10.2m

Current Assets

30.2m28.1m24.1m17.3m42.4m48.4m36.2m35.2m49.0m77.3m69.8m67.1m79.3m79.0m69.7m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(16.1m)3.0m(30.2m)(50.1m)(79.7m)

Depreciation and Amortization

1.4k4.1m5.0m4.9m5.3m

Inventories

1.3m(325.0k)(1.1m)(860.0k)

Accounts Payable

1.1m2.2m8.5m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(5.1m)(7.9m)(12.7m)(4.1m)(5.4m)(7.6m)(6.5m)(14.4m)(19.8m)(8.1m)(16.9m)(26.0m)(12.5m)(25.2m)(38.4m)

Depreciation and Amortization

1.3m2.7m1.3m2.5m3.8m1.2m2.4m3.7m1.2m2.5m3.8m

Inventories

345.0k1.4m1.3m2.3m(830.0k)936.0k1.9m(1.1m)(189.0k)1.7m(343.0k)

Accounts Payable

306.9k988.5k1.6m532.7k4.0m2.7m2.6m1.9m4.5m(2.4m)
USDY, 2018

EV/EBIT

-4.2 x

EV/CFO

-5.3 x

Financial Leverage

-8 x
Show all financial metrics

Recro Pharma Operating Metrics

FY, 2016

Patents Issued

13
Show all operating metrics

Recro Pharma Revenue Breakdown

Embed Graph

Recro Pharma revenue breakdown by business segment: 97.5% from Manufacturing, royalty and profit sharing revenue and 2.5% from Other

Report incorrect company information

Recro Pharma News and Updates

Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018

March 24, 2019 PDUFA Goal Date for IV Meloxicam

Recro Pharma Amends IV Meloxicam License Agreement with Alkermes

Reduces 2019 Cash Requirements by $30 Million; Extends Approval Milestone Payments Over Seven Years Reduces 2019 Cash Requirements by $30 Million; Extends Approval Milestone Payments Over Seven Years

Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia

MALVERN, Pa., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the publication of previously reported Phase II clinical data for intraven…

Recro Pharma Reports Third Quarter 2018 Financial Results Raising Guidance for CDMO business for 2018

Company to Host Conference Call Today at 8:00 AM ET

Recro Pharma to Participate in Upcoming Investor Conferences

MALVERN, Pa., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that Recro Pharma management will participate in the following upcoming i…

Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018

MALVERN, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced three poster presentations at PAINWeek 2018, taking place September 4-8, …
Show more
Report incorrect company information

Recro Pharma Blogs

Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting

MALVERN, Pa., March 12, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced an Industry ‘Lunch and Learn’ Session at the upcoming American Academy of O…

Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility

Credit Facility with Athyrium Expanded to $125 Million MALVERN, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced that it has closed …

Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development

Publication Highlights That IV Meloxicam Has a Safety Profile Similar to Placebo and Reduces Opioid Consumption MALVERN, Pa., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other …

Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine

Publication Highlights a Pooled Analysis of IV Meloxicam’s Safety and Opioid-Reducing Effects Across Three Phase III and Four Phase II Studies MALVERN, Pa., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therap…

Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019

Conference Call and Webcast Scheduled for Tuesday, February 19, 2019 at 8:00 a.m. ET MALVERN, Pa., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, tod…

Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro Gainesville

Company Continues Long-Term, Strategic Relationship with Key Customer Recro Gainesville to be Exclusive Supplier of Ritalin LA® and Focalin XR® Capsules with “Total Revenue Per Capsule Economics” Expected to be Similar to Prior Contracts MALVERN, Pa., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Recro Ph…
Show more

Recro Pharma Frequently Asked Questions

  • When was Recro Pharma founded?

    Recro Pharma was founded in 2006.

  • Who are Recro Pharma key executives?

    Recro Pharma's key executives are Gerri Henwood, Michael Celano and Ryan D. Lake.

  • How many employees does Recro Pharma have?

    Recro Pharma has 195 employees.

  • What is Recro Pharma revenue?

    Latest Recro Pharma annual revenue is $77.3 m.

  • What is Recro Pharma revenue per employee?

    Latest Recro Pharma revenue per employee is $396.7 k.

  • Who are Recro Pharma competitors?

    Competitors of Recro Pharma include Durect, Amarin and Array BioPharma.

  • Where is Recro Pharma headquarters?

    Recro Pharma headquarters is located at 490 Lapp Rd, Malvern.

  • Where are Recro Pharma offices?

    Recro Pharma has an office in Malvern.

  • How many offices does Recro Pharma have?

    Recro Pharma has 1 office.